Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Cortesi, P A ^a,b   Scalone, L ^a,b   D'Angiolella, L ^b   Belisari, A ^b   Fusco, F ^b,c   Olivieri, I ^d   Mantovani, L G ^e  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Fondazione Charta   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

^d Madonna delle Grazie Hospital of Matera   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cost effectiveness; Economic evaluation; Psoriatic arthritis; Systematic review

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC EVALUATION; FUNCTIONAL ASSESSMENT; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SOCIAL INTERACTION; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870267997     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. GLADMAN DD, ANTONI C, MEASE P, CLEGG DO, NASH P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. II):ii, 14-7.
2. OLIVIERI I, D'ANGELO S, PALAZZI C, PADULA A: Challenges in economic evaluation of psoriatic arthritis. J Rheumatol 2010;37:1086-8.
3. GLADMAN DD: Disability and quality of life consideration. Psoriatic arthritis. In: GORDON GB, RUDERMAN E, editors. Psoriatic and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag 2005;118-23.
4. SCARPA R, MANGUSO F, D'ARIENZO A et al: Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6.
5. QUEIRO R, TORRE JC, BELZUNEGUI J et al.: Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002;31:264-70.
6. TAM LS, TOMLINSON B, CHU TT et al: Cardiovascular risk profile of patients with psoriatic arthritis compared to controls, the role of inflammation. Rheumatology (Oxford) 2008;47:718-23.
7. ZACHARIAE H: Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
8. DONAHUE KE, JONAS D, HANSEN RA et al.: Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. Report no.: 12-EHC024-EF.
9. GLADMAN DD, SHUCKETT R, RUSSELL ML, THORNE JC, SCHACHTER RK: Psoriatic arthritis-clinical and laboratory analysis of 220 patients. Q J Med 1987;62:127-41.
10. GLADMAN DD, STAFFORD-BRADY F, CHANG CH, LEWANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
11. TORRE ALONSO JC, RODRIGUEZ PEREZ A, ARRIBAS CASTRILLO JM, BALLINA GARCIA J, RIESTRA NORIEGA JL, LOPEZ LARREA C: Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50.
12. MCHUGH NJ, BALACHRISHNAN C, JONES SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778-83.
13. BRODSZKY V, BÁLINT P, GÉHER P et al.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;20:199-205.
14. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74
15. MOSCA M, BOMBARDIERI S: Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 2007;25(Suppl. 47):107-13.
16. GLADMAN DD, FAREWELL VT, WONG K, HUSTED J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
17. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupuserythematosus. Clin Exp Rheumatol 2011;29(Suppl. 68):S126-9.
18. PEREDA C, NISHISHINYA M, MARTINEZ LOPEZ J, CARMONA L: Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2012;30:282-9.
19. SALVARANI C, PIPITONE N, MARCHESONI A et al.: Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011;29:(Suppl. 66): 28-41.
20. MEASE PJ, KIVITZ AJ, BURCH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
21. ANTONI CE, KAVANAUGH A, VAN DER HEIJDE D et al.: Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76.
22. MEASE PJ, GLADMAN DD, RITCHLIN CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
23. KAVANAUGH A, ANTONI CE, GLADMAN D et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-43.
24. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
25. GILES JT, BATHON JM: Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-34.
26. OLIVIERI I, DE PORTU S, SALVARANI C et al.: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 2008;47:1664-70.
27. TURCHETTI. G, PALLA I, PIEROTTI F, CUSCHIERI A: Economic evaluation of da Vinci-assisted robotic surgery: a systematic review. Surgical Endoscopy 2012;26:598-606.
28. MANTOVAN I (Ed.), L'Health Technology Assessment. Principi, Concetti, Strumenti Operativi, II Sole 24ore Libri, Milano, 2011.
29. TURCHETTI, G, SPADONI E, GEISLER E: Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine 2010;29:70-6.
30. TURCHETTI G: L'Health Technology Assessment. Riflessioni sulla dimensione e sulle implicazioni organizzative, in MANTOVANI L. (Ed.), L'Health Technology Assessment. Principi, Concetti, Strumenti Operativi, II Sole 24ore Libri, Milano, 2011.
31. JAVITZ HS, WARD MM, FARBER E, NAIL L, VALLOW SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-60.
32. HUSCHER D, MERKESDAL S, THIELE K, ZEIDLER H, SCHNEIDER M, ZINK A: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
33. BARRA L, POPE JE, PAYNE M: Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009;36:1421-8.
34. ZHU TY, TAM LS, LEUNG YY: Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010;37:1214-20.
35. POOLE CD, LEBMEIER M, ARA R, RAFIA R, CURRIEC J. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford) 2010;49:1949-56.
36. KVAMME MK, LIE E, KVIEN TK, KRISTIANSEN IS: Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life followup of patients in the NOR-DMARD registry. Rheumatology (Oxford) 2012;51:1618-27
37. CUMMINS E, ASSEBURG C, PRASAD M, BUCHANAN J, PUNEKAR YS: Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2011 Jul. 1. [Epub ahead of print]
38. CUMMINS E, ASSEBURG C, PUNEKAR YS, SHORE E, MORRIS J, BRIGGS A, FENWICK E: Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health 2011;14:15-23.
39. ABBOTT LABORATORIES LTD: Adalimumab (HUMIRA): Multiple technology appraisal of adalimumab, etanercept and infliximab for psoriatic arthritis National Institute for Health and Clinical Excellence (NICE) Health Technology Appraisal. Maidenhead: Abbott Laboratories Ltd; 2009.
40. SCHERING-PLOUGH: REMICADE (infliximab): Remicade in the treatment of Psoriatic Arthritis (PsA) in the United Kingdom. A submission to the National Institute of Clinical Excellence: Welwyn Garden City: Schering-Plough Ltd; 2009.
41. WYETH PHARMACEUTICALS: Etanercept (ENBREL): Appraisal of the clinical and costeffectiveness of etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. An appraisal submission for the National Institute of Health and Clinical Excellence. Maidenhead: Wyeth; 2009.
42. BOJKE L, EPSTEIN D, CRAIG D et al.: Modeling the cost-effectiveness of biologic treatments for psoriatic arthritis, Rheumatology 2011;50:iv39-iv47.
43. BANSBACK NJ, ARA R, BARKHAM N et al.: Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006;45:1029-38.
44. EANDI M, SALVARANI C: Pharmacoeconomic analysis of biological drugs for the treatment of psoriatic arthritis [in Italian]. Farmacoeconomia e Percorsi Terapeutici 2006;7:171-86.
45. BRAVO VERGEL Y, HAWKINS NS, CLAXTON K et al.: The cost effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007;46:1729-35.
46. SIZTO S, BANSBACK N, FELDMAN SR, WILLIAN MK, ANIS AH: Economic evaluation of systemic therapies for moderate to severe psoriasis Br J Dermatol 2009;160:1264-72.
47. KAVANAUGH A, MCINNES I, MEASE P et al.: Golimumab, a new human tumor necrosis factor-a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 2009;60:976-86.
48. ANTONI C, KRUEGER G, DE VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64; 1150-7.
49. ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;4:1227-36.
50. GRAY AM, RIVERO-ARIAS O, CLARKE PM: Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29.
51. BRAZIER JE, ROBERTS J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9.
52. MEASE PJ, ORY P, SHARP JT et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
53. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
54. RITCHLIN CT, KAVANAUGH A, GLADMAN DD et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009 Sep; 68:1387-94.
55. SMITH CH, ANSTEY AV, BARKER JN et al.: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
56. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE: Final Appraisal Determination: Efalizumab and Etanercept for the Treatment of Adults with Psoriasis. 2005. Available at: http://www.nice.org.uk/guidance/index.jsp?action= download&r=true&o=33356 (last accessed 30 May 2012).
57. STERRY W, BARKER J, BOEHNCKE WH et al.: Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151:3-17.
58. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl.73):S72-S84.
59. TURCHETTI G, SCALONE L, DELLA CASA ALBERIGHI O et al.: The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 2012;30(Suppl. 73):S64-S71.
60. MOSCA M, BOUMPAS D, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012;30(Suppl. 73):S112-S115.
61. TURCHETTI G, YAZDANY J, PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl.73):S116-S122.
62. PALLA I, TRIESTE L, TANI C et al.: A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 2012;30(Suppl. 73):S136-S141.
63. TRIESTE L, PALLA I, FUSCO F et al.: The economic impact of gout: systematic literature review. Clin Exp Rheumatol 2012;30(Suppl. 73):S145-S148
64. TRIESTE L, PALLA I, BALDINI C et al: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.